Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 13 July 2026 to Question 15321 on Innovation and Technology: Obesity, whether the evaluation activity will be independent of Eli Lilly and Company; whether it will include control groups, randomisation or other comparative evaluation methods; and whether the results will be published.

The Obesity Pathway Innovation Programme evaluation has been commissioned independently through the National Institute for Health and Care Research and is entirely independent of Eli Lilly and Company. The evaluation team is currently working with funded projects to understand service delivery models and planned data collection, with the final evaluation framework being developed by Autumn 2026. The findings of this independent evaluation will inform national decision-making, including future evidence requirements, and the outputs of the independent evaluation will be disseminated and made publicly available as appropriate.